Lorlatinib as a treatment for ALK-positive lung cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0184
Abstract: Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, has been approved as a treatment for ALK-positive lung cancer. This review provides information regarding the pharmacology and clinical features of lorlatinib, including its efficacy and associated adverse… read more here.
Keywords: positive lung; lung cancer; treatment alk; alk positive ... See more keywords
ALK Inhibitors in the Treatment of ALK Positive NSCLC
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2018.00557
Abstract: Background: ALK inhibitors have shown positive advance in the treatment of ALK+ NSCLC. They have achieved better results in prolonging the progression free survival and improving quality of life in comparison to chemotherapy. We have… read more here.
Keywords: positive nsclc; alk inhibitors; alk; treatment alk ... See more keywords